Differential regulation of c-Met signaling pathways for synovial cell function by Seiji Shibasaki et al.
a SpringerOpen Journal
Shibasaki et al. SpringerPlus 2014, 3:554
http://www.springerplus.com/content/3/1/554RESEARCH Open AccessDifferential regulation of c-Met signaling pathways
for synovial cell function
Seiji Shibasaki1,2*, Sachi Tsunemi1, Sachie Kitano2, Masahiro Sekiguchi2, Hajime Sano2 and Tsuyoshi Iwasaki2,3Abstract
We previously demonstrated that blocking the hepatocyte growth factor (HGF) receptor, c-Met, using a HGF antagonist,
NK4, inhibited arthritis in a rheumatoid arthritis (RA) model mice. In the present study, we investigated the role of c-Met
signaling in synovial cell function. We demonstrated that synovial tissues from RA patients and MH7A cells, a human RA
synovial cell line, expressed HGF and c-Met. HGF and c-Met expression in RA synovium was increased compared to
osteoarthritis synovium suggesting increased c-Met signaling in RA synovial cells. The c-Met inhibitor, SU11274, inhibited
ERK1/2 and AKT phosphorylation in HGF-stimulated MH7A cells. MEK and PI3K inhibitors suppressed production of matrix
metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE2) by MH7A cells,
suggesting that c-Met-MEK-ERK and c-Met-PI3K-AKT pathways are involved positively regulating MH7A cell function.
Although SU11274 suppressed MMP-3 and VEGF production it enhanced PGE2 production by MH7A cells suggesting
that negative regulation by c-Met signaling, independent of the MEK-ERK and PI3K-AKT pathways, is involved in PGE2
production. Blocking c-Met signaling may be therapeutically useful to inhibit angiogenesis and cartilage and bone
destruction by inhibiting VEGF and MMP-3 production, while enhancing PGE2 production in synovial cells in RA.
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Rheumatoid arthritis (RA) is characterized by an aggres-
sive synovial expansion due to angiogenesis and subse-
quent destruction of the underlying cartilage and bone
(Szekanecz and Koch 2008, Scot et al. 2010, Szekanecz
et al. 2010). Synovial cells produce inflammatory media-
tors, proteases, and angiogenic growth factors such
as prostaglandin E2 (PGE2), matrix metalloproteinases
(MMPs), and vascular endothelial growth factor (VEGF)
(Pap et al. 2000).
MMPs are responsible for the destruction of cartilage
and bone in RA joints. In particular, MMP-1 and MMP-3
are critical proteases in tissue degradation in RA
(Walakovits et al. 1992, Green et al. 2003). PGE2 plays a
major role in angiogenesis through the expression of VEGF
in rheumatoid synovium (Ben-Av et al. 1995). Moreover,
PGE2 has been shown to trigger bone resorption by osteo-
clasts (Mino et al. 1998) suggesting that the inflammation* Correspondence: seiji@huhs.ac.jp
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synovial cells (Sano et al. 1992). TNF-a is a well-known
cytokine that stimulates the production of MMPs and
PGE2 through activation of intracellular signaling pathways
including mitogen-activated protein kinase (MAPK) and
activator protein-1 (AP-1) (Han et al. 2001, Reunanen et al.
2002, Martel-Pelletier et al. 2003, Akaogi et al. 2006).
New blood vessel formation is critically important for
synovial expansion in RA. Angiogenic growth factors,
such as VEGF and hepatocyte growth factor (HGF), en-
hance angiogenesis and induce synovial cell proliferation
(Nagashima et al. 2001, Szekanecz et al. 2009, 2010).
The HGF receptor, c-Met, appears to induce synovial
cell proliferation in RA. We previously demonstrated
that blocking c-Met signaling using a HGF antagonist,
NK4, inhibited arthritis in a RA model of SKG mice
(Tsunemi et al. 2013).
SU11274 is a prototypic anti-c-Met small molecule
and an effective inhibitor of HGF-dependent signaling.
SU11274 abrogates HGF-induced phosphorylation of
c-Met and its downstream signal (Sattler et al. 2003).
In the present study, we examined the effect of blockings an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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function using a human synovial cell line in vitro.
Materials and methods
Cell line and cell culture
MH7A synovial cells isolated from intra-articular soft
tissues of the knee joints of RA patients were ob-
tained from Riken Cell Bank (Saitama, Japan). MH7A
is a cell line established by transfecting with the SV40
T antigen (Miyazawa et al. 1988). MH7A cells were
cultured in RPMI 1640 (Sigma, St. Louis, MO) con-
taining 10% heat-inactivated fetal bovine serum (FBS)
(Whittaker, Walkersville, MD), 100 units/ml of penicillin
and 100 μg/ml of streptomycin (Invitrogen, San Diego, CA)
at 37°C in an atmosphere of 5% CO2 in air.
Immunohistochemical analysis of HGF and c-Met
expression in RA synovium
Synovial tissue specimens isolated from patients with
RA and osteoarthritis (OA) at the time of arthroscopic
biopsy or total joint replacement were stained as re-
ported previously (Kitano et al. 2006). Briefly, synovial
tissue specimens were preserved in 10% formalin, em-
bedded in paraffin, and serially sectioned onto micro-
scope slides at a thickness of 4 μm. Synovial tissues were
stained with either anti-human c-Met antibody (1:200
dilution in PBS, rabbit IgG: Santa Cruz Biotechnology)
or anti-human HGF antibody (1:200 dilution in PBS,
rabbit IgG: Santa Cruz Biotechnology), washed, incu-
bated with biotinylated goat anti-rabbit IgG (1:1000 dilu-
tion in PBS: Santa Cruz Biotechnology), washed, incubated
with avidin-biotinylated horseradish peroxidase complex
(ABC) and diaminobenzidine tetrahydrochloride ([DAB],
Elite kit; Vector Laboratories, Inc., Burlingame, CA, USA),
and counterstained with Mayer’s hematoxylin. All pa-
tients gave informed consent, and the Institutional Medical
Ethics Committee approved the study protocol.
Western blot analysis
Western blot analysis was performed as reported previ-
ously (Dong et al. 2001). Briefly, MH7A cells (1 × 107
cells/well) were lysed in RIPA lysis buffer (Santa Cruz
Biotechnology, CA), and protein content was deter-
mined using Bio-Rad protein assay reagent (Bio-Rad,
Hercules, CA) with bovine serum albumin as a standard.
Each sample (20 μg) was resolved on 1% polyacrylamide
gels under denaturing conditions and then transferred
to 0.45-μm nitrocellulose membranes. After blocking
overnight at 4°C with 5% nonfat milk in Tris-buffered
saline-0.01% Tween 20 (Santa Cruz Biotechnology),
membranes were incubated with primary antibodies
against either phospho-extracellular signal-regulated kin-
ase (ERK) 1/2, phospho-AKT, or β-actin (1:1000 dilution
in PBS; Santa Cruz Biotechnology) after 12 h stimulationin the presence of HGF (10 ng/ml) with or without the
c-Met inhibitor, SU11274 (Tocris Bioscience, UK). After
washing the membranes with Tris buffered saline–
0.05% Tween 20 (washing buffer), HRP-conjugated goat
anti-rabbit secondary antibody (1:1000 dilution in PBS;
Santa Cruz Biotechnology) was added, followed by incuba-
tion for 45 min. After further washing, the color was devel-
oped with luminol reagent (Santa Cruz Biotechnology),
and HRP activity of the blots was analyzed using an
LAS1000 imager. Luminol staining was done according to
manufacturer’s instructions (Santa Cruz).
Measurement of PGE2, VEGF and MMP-3 production by
MH7A cells
MH7A cells (2 × 104 cells/well) were plated in flat-
bottomed 24-well microplates and cultured with or
without either NK4 or c-Met inhibitor, SU11274 (Tocris
Bioscience) in the presence or absence of 100 ng/ml
TNF-α (Genzyme Pharmaceuticals, Cambridge, MA,
USA). MH7A cells (2 × 104 cells/well) were also cultured
with or without either the MEK inhibitor, PD98059
(Cell Signaling Technology, MA), or the PI3K inhibitor,
LY294002 (Cell Signaling Technology), in the presence
or absence of 100 ng/ml TNF-α. After 72 hours of incu-
bation, PGE2, VEGF and MMP-3 production was deter-
mined by assaying supernatants with ELISAs using either
anti-human PGE2, VEGF and MMP-3 monoclonal anti-
bodies (Genzyme), respectively, according to the manu-
facturer's protocol.
Statistical analysis
Results are expressed as the mean ± SEM. The signifi-
cance of the difference between the experimental results
and control values was determined by a Student’s t-test.
P values less than 0.05 were considered significant.
Results
HGF and c-Met expression in the synovium of RA patients
To examine whether c-Met signaling pathways are in-
volved in the pathogenesis of RA, we examined the ex-
pression of HGF and c-Met in the synovium of OA and
RA patients. Immunohistochemical analysis demon-
strated that HGF and c-Met expression in synovial lining
cells was higher in RA patients than in OA patients
(Figure 1A). We also demonstrated that MH7A cells, a
synovial cell line established from RA patients, expressed
HGF and c-Met by Western blot analysis (Figure 1B).
These results suggest that c-Met protein is increased in the
synovial tissues of RA patients.
SU11274 inhibits ERK1/2 and AKT phosphorylation by
MH7A cells
MEK/ERK and PI3-AKT signaling pathways can be acti-
vated by a variety of growth factors such as insulin and
Figure 1 c-Met and HGF expression in synovial cells. A. Immunohistochemical analysis of joints. c-Met and HGF expression in synovial
lining cells of RA patients was higher than in OA patients. HGF was expressed in infiltrating mononuclear cells (SL, synovial lining cell
layer; M, mononuclear cells). Original magnification ×200. B. Western blot analysis of MH7A cells. c-Met and HGF were expressed in
MH7A cells.
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AKT was downstream of c-Met signaling, we examined
the effect of the SU11274 inhibitor on ERK1/2 and AKT
phosphorylation in response to HGF treatment. Stimu-
lation of MH7A cells with HGF led to a significant
increase in phosphorylation of ERK1/2 and AKT. Con-
versely, although treatment with the c-Met inhibitor
(0.25 nM) did not affect treatment with the c-Met in-
hibitor (2.5 nM) reduced HGF-induced ERK1/2 and
AKT phosphorylation, indicating that minimal dose of
the c-Met inhibitor to block HGF-induced p-ERK1/2
and p-AKT expression is 0.25 nM (Figure 2). TheseFigure 2 Effects of the SU11274 inhibitor on ERK1/2 and AKT phospho
with or without SU11274 (0.25 - 2.5 nM) and p-ERK1/2 and p-AKT expression
expression as a control. Representative data of p-ERK1/2 and p-AKT expressiresults suggest that c-Met-MEK-ERK and c-Met-PI3-
AKT signaling pathways are utilized in MH7A cells.
Both MEK-ERK and PI3-AKT signaling pathways are
involved in the production of MMP-3, VEGF and PGE2
by MH7A cells
To confirm the involvement of MEK-ERK and PI3-AKT
signaling pathways in the production of MMP-3, VEGF
and PGE2, we examined whether pretreatment with either
MEK or PI3K inhibitors affected MMP-3, VEGF and PGE2
production. Both the MEK inhibitor, PD98059 and the
PI3K inhibitor, LY294002, inhibited MMP-3, VEGF andrylation in MH7A cells. MH7A cells were treated with HGF (10 ng/ml)
was determined by Western blot analysis. We also determined β-actin
on by MH7A cells is shown.
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both MEK-ERK and PI3-AKT signaling pathways are in-
volved in MMP-3, VEGF and PGE2 production.
Blocking c-Met signaling using NK4 or SU11274 inhibits
MMP-3 and VEGF, but enhances PGE2 production by
MH7A cells
MH7A cells were treated with either NK4 or the c-Met
inhibitor, SU11274, in the presence or absence of TNF-α
for 72 hours and the production of MMP-3, VEGF and
PGE2 was determined by ELISA. TNF-α significantly en-
hanced MMP-3 and PGE2, but not VEGF production by
MH7A cells. Both NK4 and SU11274 inhibited MMP-3
and VEGF, but enhanced PGE2 production by MH7A cells
(Figure 4A). We next examined the effect of different doses
of SU11274 on MH7A cells. As shown in Figure 4B,
SU11274 dose-dependently inhibited MMP-3 and VEGF,
but enhanced PGE2 production by MH7A cells (Figure 4B).
These results indicate that negative regulation by c-Met
signaling independent of the MEK-ERK and PI3K-AKT
pathway is also involved in PGE2 production.
Discussion
We demonstrated that HGF and its receptor, c-Met, are































































































Figure 3 Effects of MEK or PI3K inhibitors on the production of MMP
were cultured with the MEK inhibitor, PD98059 (10 - 60 nM), in the presence
VEGF and PGE2 production was determined by analysis of supernatants usin
inhibitor, LY294002 (10 - 60 nM), in the presence or absence of 100 ng/ml T
was determined by analysis of supernatants using ELISA. Data represent thec-Met expression is increased in RA patients, but not
OA patients. Synovial expansion is dependent on new
blood vessel formation, which is important for the de-
livery of oxygen, nutrients, and inflammatory cells to
the lesions of RA (Szekanecz and Koch 2008, Scot et al.
2010, Szekanecz et al. 2010). It has been reported that
HGF and c-Met are expressed in synovial tissues in pa-
tients with RA (Nagashima et al. 2001). HGF in the syn-
ovial fluid of patients with RA is produced by synovial
cells and is related to disease activity (Yukioka et al. 1994).
Taken together, HGF may contribute to the development
of RA by its potent angiogenic activities, which stimulate
synovial cell proliferation.
We demonstrated that inhibition of c-Met signaling
resulted in decreased VEGF and MMP-3 production by
MH7A cells. VEGF is a potent angiogenic factor that is
pivotal in RA pathogenesis. The role for HGF in VEGF
production has been implicated in some cell types such as
squamous cell carcinoma and synovial cells. It was demon-
strated that c-Met signaling activates the PI3-AKT signal-
ing pathway leading to up-regulation of VEGF expression
(Dong et al. 2001, Lin et al. 2012). The present study
demonstrated that c-Met signaling activates both the
MEK-ERK and PI3-AKT signaling pathways leading to up-


























































































-3, VEGF and PGE2 by MH7A cells. A. MH7A cells (2 x 104 cells/well)
or absence of 100 ng/ml TNF-α. After 72 hours of incubation, MMP-3,
g ELISA. B. MH7A cells (2 x 104 cells/well) were cultured with the PI3K
NF-α. After 72 hours of incubation, MMP-3, VEGF and PGE2 production


















































































































































Figure 4 Effects of blocking c-Met signaling on the production of MMP-3, VEGF, and PGE2 by MH7A cells. A. MH7A cells (2 x 104 cells/well)
were cultured with or without either NK4 or SU11274 in the presence or absence of 100 ng/ml TNF-α. After 72 hours of incubation, MMP-3, VEGF
and PGE2 production was determined by analysis of supernatants using ELISA. B. MH7A cells (2 x 104 cells/well) were cultured with different dose
of SU11274 in the presence or absence of 100 ng/ml TNF-α. After 72 hours of incubation, MMP-3, VEGF and PGE2 production was determined by
analysis of supernatants using ELISA. Data represent the mean ± SD of three independent experiments. *P < 0.01. NS, not significant.
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mechanisms of HGF in which increasing MMP expression
promoted collagen degradation (Esposito et al. 2009).
Addition of HGF to fibroblast cultures of scleroderma
patients significantly decreased collagen production and
increased MMP-1 expression and activity (Jinnin et al.
2005). Addition of HGF to keloid fibroblastic cells signifi-
cantly increased the mRNA expression of MMP-1 and
MMP-3 in a dose-dependent manner (Lee et al. 2011).
This means that HGF may have a therapeutic effect on ke-
loids that is similar to pathologic dermal fibrosis seen in
scleroderma (Jinnin et al. 2005, Lee et al. 2011). In a previ-
ous study, we demonstrated that HGF gene transfection
improved dermal sclerosis in mouse model of scleroderma
(Iwasaki et al. 2006). The present results that the blocking
c-Met signaling using the c-Met inhibitor (SU11274)
inhibited MMP-3 production by MH7A cells provide sup-
port for the previous findings.
c-Met is a proto-oncogene that encodes a protein
known as the HGF receptor (Liu et al. 1994, Zarnegar
and Michalopoulos 1995). Upon HGF stimulation, c-Met
induces c-Met kinase catalytic activity, which triggers
transphosphorylation of tyrosines Tyr-1234 and Tyr-1235.
These two tyrosines engage various signal transducers toinitiate a whole spectrum of biological activities driven by
c-Met. Two major signaling pathways, MEK/ERK and PI3/
AKT, are activated by c-Met (Bottaro et al. 1991, Graziani
et al. 1991, O'Brien et al. 2004, Mahtouk et al. 2010). We
observed that both ERK1/2 and AKT phosphorylation was
enhanced by HGF and was suppressed by the c-Met inhibi-
tor. We also observed that both MEK and PI3K inhibitors
suppressed VEGF and MMP-3 production. These results
indicate that both c-Met-MEK/ERK and c-Met-PI3/AKT
pathways are involved in the production of MMP-3 and
VEGF by MH7A cells.
In contrast to the inhibitory effect of the c-Met inhibi-
tor on MMP-3 and VEGF production, blocking c-Met
signaling enhanced PGE2 production by MH7A cells.
Previous work reported conflicting results that c-Met
signaling can promote PGE2 production in colorectal
cancer cells via COX-2 up-regulation and 15-PGDH
down-regulation at the protein and messenger RNA
level (Moore et al. 2009). They demonstrated that both
ERK and AKT signals are required for COX-2 protein
up-regulation and 15-PGDH down-regulation down-
stream of c-Met. Furthermore, SU11274 reduced COX-2
expression and increased 15-PGDH expression in high
c-Met-expressing cells (Moore et al. 2009). We still do
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enhances PGE2 production. Supporting our findings,
Zhang et al., performed in vitro experiments on rabbit
tendon cells and in vivo experiments in a mouse Achilles
tendon injury model. They demonstrated that HGF
treatment suppressed IL-1β-induced gene expression of
COX-1, COX-2, and the production of PGE2 in tendon
cell culture. Injection of HGF into wounded mouse
Achilles tendons in vivo decreased PGE2 production in
the tissues (Zhang et al. 2013).
HGF is known to function both as an anti-inflammatory
agent and as an anti-fibrotic regulator (Gong 2008).
Its anti-inflammatory action is primarily mediated by
the disruption of signaling by the transcription factor,
NF-kB, which is a critical regulator of inflammation.
This was demonstrated both in an in vivo renal inflam-
mation mouse model (Giannopoulou et al. 2008) and in
human chondrocytes in vitro (Bendinelli et al. 2010). Such
a c-Met-mediated negative signal for PGE2 production, in-
dependent of the c-Met-MEK-ERK and c-Met-PI3-AKT
pathways, may be responsible for the anti-inflammatory
effects of HGF on PGE2 production observed in this
study. However, HGF has strong angiogenic activities
which are crucial for synovial cell proliferation in RA.
In this article, we suggested that blocking c-Met sig-
naling inhibited angiogenesis and cartilage and bone
destruction by the inhibition of VEGF and MMP-3
production by synovial cell line, respectively. We pre-
viously reported that blocking c-Met signaling using
HGF antagonisit, NK4, inhibited arthritis in RA model of
SKG mice (Tsunemi et al. 2013). Therefore, we think that
although blocking c-Met signaling may enhances inflam-
matory responses, it is effective for the treatment of RA
by its strong inhibition of angiogenesis and protease-
mediated bone destruction.
In conclusion, this is the first report to demonstrate
the differential regulation of c-Met signaling pathways
for synovial cell function. Blocking c-Met signaling may
be useful to inhibit angiogenesis and cartilage and bone
destruction by inhibiting VEGF and MMP-3 production,
respectively, while it enhances PGE2 production by syn-
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